|
FY2026
12 months to Jul 31, 2026
|
FY2025
12 months to Jul 31, 2025
|
FY2024
12 months to Jul 31, 2024
|
FY2023
12 months to Jul 31, 2023
|
FY2022
12 months to Jul 31, 2022
|
|
|---|---|---|---|---|---|
| Operating expenses: | |||||
| Research, development, and clinical trial expenses, net | |||||
| General and administrative expenses | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Financial income (expenses), net | |||||
| Change in fair value of the warrant liability | |||||
| Unrealized gain on short-term investment | |||||
| Share of loss on equity investment | |||||
| Net loss for the year | |||||
| Net loss attributable to non-controlling interest | |||||
| Net loss for the year attributable to BriaCell | |||||
| Net loss per share attributable to BriaCell - basic | |||||
| Net loss per share attributable to BriaCell - diluted | |||||
| Weighted average number of shares used in computing net basic earnings per share of common shares | |||||
| Weighted average number of shares used in computing net diluted earnings per share of common shares | |||||
Loading...